Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy

Urology

Volumn 49, Issue 1, 1997, Pages 65-70

  Vander Kooy, Michael J ^a   Pisansky, Thomas M ^a,b   Cha, Stephen S ^a   Blute, Michael L ^a  

^a Cancer Center Statistics Unit   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATECTOMY; RECTUM TUMOR; RECURRENCE RISK; RECURRENT CANCER; TREATMENT PLANNING; TUMOR RECURRENCE;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0031020864     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00371-8     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Mettlin C, Jones GW, and Murphy GP: Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluations studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 43: 83-91, 1993.
3. Lu-Yao GL, and Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 343: 251-254, 1994.
4. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, and Lieber MM: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 142: 1262-1265, 1989.
5. Myers RP, and Fleming TR: Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 4: 461-472, 1983.
6. Anscher MS, and Prosnitz LR: Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 21: 941-947, 1991.
7. Epstein JI, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
8. McCarthy JF, Catalona WJ, and Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 151: 1575-1578, 1994.
9. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, and Ferrigni RG: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 69: 613-619, 1994.
10. Wu JJ, King SC, Montana GS, McKinstry CA, and Anscher MS: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 32: 317-323, 1995.
11. Abi-Aad AS, MacFarlane MT, Stein A, and deKernion JB: Detection of local recurrence after radical prostatectomy by prostate-specific antigen and transrectal ultrasound. J Urol 147: 952-955, 1992.
12. Anscher MS, and Prosnitz LR: Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 17: 953-958, 1989.
13. Forman JD, Wharam MD, Lee DJ, Zinreich ES, and Order SE: Definitive radiotherapy following prostatectomy: results and complications. Int J Radiat Oncol Biol Phys 12: 185-189, 1986.
14. Gibbons RP, Cole BS, Richardson RG, Correa RJ, Brannen GE, Mason JT, Taylor WJ, and Hafermann MD: Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 135: 65-68, 1986.
15. Hanks GE, and Dawson AK: The role of external beam radiation therapy after prostatectomy for prostate cancer. Cancer 58: 2406-2410, 1986.
16. Oas LG, Zagars GK, and Pollack A: Radiation therapy alone is not successful as salvage treatment for locally recurrent prostate cancer after radical prostatectomy (abstract). Int J Radiat Oncol Biol Phys 32: 272, 1995.
17. Perez CA, Cosmatos D, Garcia DM, Eisbruch A, and Poulter CA: Irradiation in relapsing carcinoma of the prostate. Cancer 71: 1110-1122, 1993.
18. Ray GR, Bagshaw MA, and Freiha F: External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol 132: 926-930, 1984.
19. Rosen EM, Cassady JR, Connolly J, and Chaffey JT: Radiotherapy for localized prostate carcinoma. Int J Radiat Oncol Biol Phys 10: 2201-2210, 1984.
20. Wiegel T, Bressel M, Arps H, and Hubener KH: Radiotherapy of local recurrence following radical prostatectomy. Strahlenther Onkol 168: 333-336, 1992.
21. Zietman AL, Coen JJ, Shipley WU, and Althausen AF: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology 42: 292-298, 1993.
22. Klee GG, Dodge LA, Zincke H, and Oesterling JE: Measurement of serum prostate specific antigen using IMx prostate-specific antigen assay. J Urol 151: 94-98, 1994.
23. American Joint Committee on Cancer: Manual for Staging of Cancer, 4th ed. Philadelphia, JB Lippincott, 1992, pp 181-183.
24. Utz DC, and Farrow GM: Pathologic differentiation and prognosis of prostatic carcinoma. JAMA 209: 1701-1703, 1969.
25. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
26. Kalbfleisch JD, and Prentice RL: The Statistical Analysis of Failure Time Data. New York, John Wiley & Sons, 1980.
27. Catalona WJ, and Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837-1842, 1994.
28. Murphy GP, Mettlin C, Menck H, Winchester DP, and Davidson AM: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 152: 1817-1819, 1994.
29. Trapasso JG, deKernion JB, Smith RB, and Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821-1825, 1994.
30. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
31. Hawkins CA, Bergstralh EJ, Lieber MM, and Zincke H: Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology 46: 356-364, 1995.
32. Zagars GK, von Eschenbach AC, and Ayala AG: Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 72: 1709-1725, 1993.
33. Kuban DA, El-Mahdi AM, and Schellhammer PF: Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 75: 2373-2382, 1995.
34. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, and Krane RJ: Radical prostatectomy for adenocarcinoma of the prostate. The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43: 828-833, 1994.
35. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, and Oesterling JE: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11: 2158-2166, 1993.
36. Zagars GK, Pollack A, Kavadi VS, and von Eschenbach AC: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293-306, 1995.
37. Zietman AL, Coen JJ, Shipley WU, Willett CG, and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
38. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M, and Margolese R: Significance of ipsilateral breast tumor recurrence after lumpectomy. Lancet 338: 327-331, 1991.
39. Yorke ED, Fuks Z, Norton L, Whitmore W, and Ling CC: Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer. Cancer Res 53: 2987-2993, 1993.
40. Pilepich MV, Krall J, George FW, Asbell SO, Plenk HD, Johnson RJ, Stetz J, Zinninger M, and Walz BJ: Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 10: 1861-1867, 1984.
41. Viggiano TR, Zighelboim J, Ahlquist DA, Gostout CJ, Wang KK, and Larson MV: Endoscopic Nd:YAG laser coagulation of bleeding from radiation proctopathy. Gastrointest Endosc 39: 513-517, 1993.
42. Thompson IM, Paradelo JC, Crawford ED, Coltman CA, and Blumenstein B: An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing. Urology 44: 804-811, 1994.